MediWound Ltd.
MDWDNasdaq
$14.61
0.0%Jul 17 close · end-of-day
Price
1Y↓ -27.0%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
No screener snapshot for this ticker.
Company profile
MediWound Ltd. markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma.
- CEO
- Ofer Gonen
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 80
- Website
- mediwound.com
Earnings
No reported earnings periods on file.
Financial statements
No annual data.
No quarterly data.
Company news
May 27, 2026
- 53d agoMediWound Ltd (MDWD) Q1 2026 Earnings Call Highlights: Strategic Collaborations and Revenue ...finance.yahoo.com
- 54d agoMediWound (MDWD) Q1 2026 Earnings Transcriptfool.com
- 54d agoMediWound Q1 Earnings Call Highlightsmarketbeat.com
- 54d agoMediWound (MDWD) Reports Q1 Loss, Misses Revenue Estimatesfinance.yahoo.com
May 15, 2026
May 14, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-06-03 | SHAMIR NACHUM | Buy | 5,825 | $14.00 | $81,550.00 | filing |
| 2026-06-03 | SHAMIR NACHUM | Buy | 175 | $13.98 | $2,445.63 | filing |
| 2026-06-01 | Fox David Morton | Buy | 1,797 | $14.00 | $25,149.02 | filing |
| 2026-06-01 | Fox David Morton | Buy | 1,730 | $14.23 | $24,609.25 | filing |
| 2026-06-01 | Fox David Morton | Buy | 10 | $14.23 | $142.30 | filing |
| 2026-05-29 | Rubinstein Samuel | Buy | 150 | $14.33 | $2,149.50 | filing |
Latest 6 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.